rituximab biosimilar / Oswaldo Cruz Foundation - LARVOL DELTA

Bio-Manguinhos signs partnership with Sandoz and Bionovis for biosimilar rituximab (Pfarma) - "The Oswaldo Cruz Foundation's Institute of Technology in Immunobiologicals (Bio-Manguinhos / Fiocruz) signed a Partnership for Productive Development (PDP) with Sandoz (Novartis Group) and Bionovis for the incorporation of biosimilar rituximab, a monoclonal antibody indicated for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and for immunological diseases such as rheumatoid arthritis."

Licensing / partnership